Trial Condition(s):

Multiple myeloma

Phase 1b/2 study testing radium-223 dichloride/bortezomib/dexamethasone combination in relapsed multiple myeloma

Bayer Identifier:

17451

ClinicalTrials.gov Identifier:

NCT02605356

EudraCT Number:

2015-000427-82

Terminated/Withdrawn

Trial Purpose

This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint of the phase 1b part is to determine the optimal dose of radium-223 dichloride in combination with bortezomib/dexamethasone for the Phase 2 portion of the study.
The phase 2 part will be an international, phase 2, double-blind, randomized, placebo-controlled assessment of radium-223 dichloride versus placebo administered with bortezomib and dexamethasone, in subjects with relapsed multiple myeloma. Randomization (1:1) in the phase 2 part will be stratified by:
• Prior bortezomib treatment (yes, no)
• Prior treatment (1 prior line of treatment, >1 prior line of treatment)
Approximately 30 subjects (10 subjects per cohort) will be enrolled in the phase 1b part of the study and approximately 196 subjects will be enrolled in the phase 2 part of the study.

Inclusion Criteria
- Cytologically or histologically confirmed diagnosis of multiple myeloma
 - Subjects must have received at least 1 and not more than 3 previous lines of treatment and have had a response to treatment (i.e., achieved a minimal response [MR] or better) according to the International Myeloma Working Group (IMWG) uniform response criteria
 - Subjects must have had progressive disease according to the IMWG uniform response criteria following the last multiple myeloma treatment
 - Subjects must have measurable disease defined as at least 1 of the following (according to central laboratory results):
 -- Serum M-protein ≥1 g/dL
 -- Urine M-protein ≥200 mg/24 hours
 -- Serum free light chain (FLC) ≥10 mg/dL with abnormal ratio
 - ≥1 bone lesion identifiable by radiograph, computed tomography, magnetic resonance imaging, or bone scintigraphy
 - Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2
 - Subjects must be nonrefractory to bortezomib and had no progression during or within 60 days after completion of bortezomib
 - Absolute neutrophil count (ANC) ≥1.5 × 10e9/L, hemoglobin (Hb) ≥9.0 g/dL, and platelet count ≥75.0 × 10e9/L independent of transfusion of red blood cells (RBC) or platelet concentrates and independent of granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF)
Exclusion Criteria
- Systemic glucocorticoid therapy (prednisone >10 mg/day orally or equivalent) within the last 4 weeks prior to first dose, unless tapered and on a stable dose ≤10 mg/day for at least 1 week
 - Subjects with known POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or light chain (AL) amyloidosis
 - Plasma cell leukemia
 - Systemic anti-cancer therapy within 4 weeks prior to first dose
 - Radiation therapy in the previous 4 weeks prior to first dose except if given for pain management and involves less than 10% of the bone marrow
 - Prior treatment with radium-223 dichloride or any experimental radiopharmaceutical
 - Congestive heart failure (New York Heart Association [NYHA] class III to IV), symptomatic cardiac ischemia, cardiomyopathy, clinically relevant ventricular arrhythmia, pericardial disease, unstable angina or myocardial infarct in the previous 6 months prior to first dose, left ventricular ejection fraction <40%
 - Neuropathy ≥ Grade 2 or Grade 1 with pain

Trial Summary

Enrollment Goal
0
Trial Dates
black-arrow
Phase
1/2
Could I receive a placebo?
Yes
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Encinitas, United States, 92024

Status
Terminated
 
Locations

Investigative Site

New York, United States, 10032-3729

Status
Terminated
 
Locations

Investigative Site

Torino, Italy, 10126

Status
Terminated
 
Locations

Investigative Site

Novara, Italy, 28100

Status
Terminated
 
Locations

Investigative Site

Watertown, United States, 57201

Status
Terminated
 
Locations

Investigative Site

Jerusalem, Israel, 9112001

Status
Terminated
 
Locations

Investigative Site

Afula, Israel, 1834111

Status
Terminated
 
Locations

Investigative Site

Haifa, Israel, 31048

Status
Terminated
 
Locations

Investigative Site

Ramat Gan, Israel, 5262000

Status
Terminated
 
Locations

Investigative Site

Zerifin, Israel, 6093000

Status
Terminated
 
Locations

Investigative Site

Athens, Greece, 11528

Status
Terminated
 
Locations

Investigative Site

Rio / Patra, Greece, 26500

Status
Terminated
 
Locations

Investigative Site

Milano, Italy, 20089

Status
Terminated
 
Locations

Investigative Site

BRUXELLES - BRUSSEL, Belgium, 1090

Status
Terminated
 
Locations

Investigative Site

BRUGGE, Belgium, 8000

Status
Terminated
 
Locations

Investigative Site

YVOIR, Belgium, 5530

Status
Terminated
 
Locations

Investigative Site

LIEGE, Belgium, 4000

Status
Terminated
 
Locations

Investigative Site

Bologna, Italy, 40138

Status
Terminated
 
Locations

Investigative Site

Milano, Italy, 20132

Status
Terminated
 
Locations

Investigative Site

Firenze, Italy, 50141

Status
Terminated
 
Locations

Investigative Site

Quebec, Canada, G1R 2J6

Status
Terminated
 
Locations

Investigative Site

München, Germany, 81377

Status
Terminated
 
Locations

Investigative Site

Tübingen, Germany, 72076

Status
Terminated
 
Locations

Investigative Site

Berlin, Germany, 12203

Status
Terminated
 
Locations

Investigative Site

Mainz, Germany, 55131

Status
Terminated
 
Locations

Investigative Site

BRUXELLES - BRUSSEL, Belgium, 1200

Status
Terminated
 
Locations

Investigative Site

Winston-Salem, United States, 27157

Status
Terminated
 
Locations

Investigative Site

Barcelona, Spain, 08035

Status
Terminated
 
Locations

Investigative Site

Barcelona, Spain, 08036

Status
Terminated
 
Locations

Investigative Site

Valencia, Spain, 46017

Status
Terminated
 
Locations

Investigative Site

Palma de Mallorca, Spain, 07010

Status
Terminated
 
Locations

Investigative Site

Madrid, Spain, 28046

Status
Terminated
 
Locations

Investigative Site

Madrid, Spain, 28006

Status
Terminated
 
Locations

Investigative Site

San Sebastián, Spain, 20014

Status
Terminated
 
Locations

Investigative Site

Sevilla, Spain, 41013

Status
Terminated
 
Locations

Investigative Site

Seattle, United States, 98104

Status
Terminated
 
Locations

Investigative Site

Seoul, South Korea, 03080

Status
Terminated
 
Locations

Investigative Site

Seoul, South Korea, 137-701

Status
Terminated
 
Locations

Investigative Site

Scottsdale, United States, 85259-5404

Status
Terminated
 
Locations

Investigative Site

Pisa, Italy, 56126

Status
Terminated
 
Locations

Investigative Site

Cagliari, Italy, 09121

Status
Terminated
 
Locations

Investigative Site

Durham, United States, 27710

Status
Terminated
 
Locations

Investigative Site

Taipei, Taiwan, China, 10016

Status
Terminated
 
Locations

Investigative Site

Taipei, Taiwan, China, 11217

Status
Terminated
 
Locations

Investigative Site

Taichung, Taiwan, China, 40447

Status
Terminated
 
Locations

Investigative Site

Taipei, Taiwan, China

Status
Terminated
 
Locations

Investigative Site

Daegu, South Korea, 700-701

Status
Terminated
 
Locations

Investigative Site

Goyang-si, South Korea, 410-769

Status
Terminated
 
Locations

Investigative Site

Seoul, South Korea, 138-736

Status
Terminated
 
Locations

Investigative Site

Little Rock, United States, 72205

Status
Terminated
 
Locations

Investigative Site

Rockville, United States, 20850-6535

Status
Terminated
 
Locations

Investigative Site

Metairie, United States, 70006

Status
Terminated
 
Locations

Investigative Site

Jeollanam-do, South Korea, 519-763

Status
Terminated
 
Locations

Investigative Site

Seoul, South Korea, 135-710

Status
Terminated
 
Locations

Investigative Site

Badalona, Spain, 08916

Status
Terminated
 
Locations

Investigative Site

Reggio Emilia, Italy, 42123

Status
Terminated
 
Locations

Investigative Site

BOX HILL, Australia, 3128

Status
Terminated
 
Locations

Investigative Site

Adelaide, Australia, 5000

Status
Terminated
 

Trial Design